期刊文献+

利伐沙班降解杂质的合成 被引量:1

Synthesis of the Degradation Impurity of Rivaroxaban
原文传递
导出
摘要 目的合成利伐沙班的3个降解杂质,从而加强对Xa因子抑制剂类抗凝药利伐沙班原料药的质量控制。方法利伐沙班(1)经开环反应得到杂质A;杂质A经水解反应得到杂质B;杂质A经取代反应得到杂质C。结果合成的3种降解杂质的结构经~1H-NMR、^(13)C-NMR和MS确证,纯度经HPLC检测均>99.0%。结论 3个杂质可作为利伐沙班原料药质量控制的杂质对照品。 OBJECTIVE To perform the quality of rivaroxaban which was a kind of anticoagulant drug, three degradation impurities A, B and C were synthesized and characterized. METHODS Rivaroxaban (1 ) was used as starting material to prepare Impurity A , impurity B was synthesized by hydrolyzing impurity A , and impurity C was obtained from impurity A by substitution reaction. RESULTS The structures of the three impurities had been verified by 1^H-NMR and 13^C-NMR and MS. Their purities were over 99.0% (detected by HPLC). CONCLUSION The synthetic degradation impurities can be used as the reference substance of the impurities in the quality control of rivaroxaban.
作者 彭嘉勋 毛雨
出处 《中国现代应用药学》 CAS CSCD 2017年第5期700-702,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 利伐沙班 降解杂质 合成 rivaroxaban degradation impurity synthesis
  • 相关文献

参考文献6

二级参考文献50

  • 1陈蓉,谢梅林.新型抗血栓药物作用机制研究进展[J].中国药理学通报,2004,20(8):857-860. 被引量:6
  • 2王海萍,王健伟,韩金祥,贾友苏,洪涛.因子Ⅹa抑制剂研究进展[J].生物技术通讯,2004,15(5):495-497. 被引量:3
  • 3PINTO JP D,ORWAT JM,KOCH S,et al. Discovery of 1-(4-methoxyphenyl ) -7-oxo-6-( d-( 2-oxopiperidin-1-yl ) phenyl )-4,5,6, 7-tetrahydro-1 H-pyrazolo [ 3,4-c] pyridine-3 -carboxamide ( apixa- ban, BMS-562247 ) , a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa [ J ]. J Med Chem,2007,50 ( 22 ) : 5339 - 5356.
  • 4MEDERSKI WKR W, DORSCH D, ANZALI S, et al. Halothio phenebenzimidazoles as P1 surrogates of inhibitors of blood coagu lation factor Xa [J]. Bioorg Med Chem Lett, 2004, 14 (14) 3763 - 3769.
  • 5ROEHRIG S,STRAUB A,POHLMANN J,et al. Discovery of the novel antithrombotic agent 5-chloro-N-(1 ( 5S ) -2-oxo-3-[ 4-( 3- oxomorpholin-4-yl) phenyl ] -1, 3-oxazolidin-5-yl I methyl ) thiophene-2-carboxamide(BAY59-7939) : an oral, direct factor Xa inhibitor[J]. J Med Chem ,2005,48 ( 19 ) :5900 - 5908.
  • 6拜尔公司.取代的噁唑烷酮和其在血液凝固领域中的应用:德国,CN00818966.8[P].2003-08-06.
  • 7Becker R, Berkowitz SD, Breithardt G, et al. Rivaroxaban- once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study [J]. Am Heart J, 2010, 159 (3) : 340-347.
  • 8Roehring S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-( { (5S)-2- oxo-3- [4- (3-oxomorpholin-4-yl) phenyl] - 1,3-oxazolidin-5- yl}methyl) thiophene-2-carboxamide- (BAY-59-7939) : an oral, direct factor Xa inhibitor EJ]. J Med Chem, 2005, 48: 5900-5908.
  • 9Mangion B. Process for determining the suitability for distribution of a batch of a thiophene-2-carboxamide derivative: WO, 2012035057 [P]. 2012-03-22.
  • 10Mark A, Matulenko, Meyers AI. Total synthesis of (-)-tetrahydropalmatine via chiral formamidine carbanions: unexpected behavior with certain ortho-substituted electrophiles EJ]. J Org Chem, 1996, 61: 573-580.

共引文献35

同被引文献4

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部